NCT06726200View on ClinicalTrials.gov

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

January 15, 2029

Study Completion Date

January 15, 2029

Conditions
Opioid Use Disorder
Interventions
DRUG

Buprenorphine + naloxone (Suboxone)

Participants randomized to sublingual buprenorphine naloxone will initiate treatment based on clinical guidelines/standard of care

DRUG

Buprenorphine Injection

Participants randomized to injectable buprenorphine naloxone will receive a 300mg injection after receiving/tolerating a single 4/1 mg sublingual buprenorphine/naloxone dose

Trial Locations (1)

10019

RECRUITING

Substance Treatment and Research Service, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Rachel R. Luba

OTHER